Cytokine therapy reverses NK cell anergy in MHC-deficient tumors.

Various cytokines have been evaluated as potential anticancer drugs; however, most cytokine trials have shown relatively low efficacy. Here, we found that treatments with IL-12 and IL-18 or with a mutant form of IL-2 (the "superkine" called H9) provided substantial therapeutic benefit for mice specifically bearing MHC class I-deficient tumors, but these treatments were ineffective for mice with matched MHC class I+ tumors. Cytokine efficacy was linked to the reversal of the anergic state of NK cells that specifically occurred in MHC class I-deficient tumors, but not MHC class I+ tumors. NK cell anergy was accompanied by impaired early signal transduction and was locally imparted by the presence of MHC class I-deficient tumor cells, even when such cells were a minor population in a tumor mixture. These results demonstrate that MHC class I-deficient tumor cells can escape from the immune response by functionally inactivating NK cells, and suggest cytokine-based immunotherapy as a potential strategy for MHC class I-deficient tumors. These results suggest that such cytokine therapies would be optimized by stratification of patients. Moreover, our results suggest that such treatments may be highly beneficial in the context of therapies to enhance NK cell functions in cancer patients.

[1]  D. Raulet,et al.  NK cell self tolerance, responsiveness and missing self recognition. , 2014, Seminars in immunology.

[2]  Jeffry D. Sander,et al.  CRISPR-Cas systems for editing, regulating and targeting genomes , 2014, Nature Biotechnology.

[3]  Neville E. Sanjana,et al.  Genome-Scale CRISPR-Cas9 Knockout Screening in Human Cells , 2014, Science.

[4]  A. Cerwenka,et al.  Sustained effector function of IL-12/15/18–preactivated NK cells against established tumors , 2012, The Journal of experimental medicine.

[5]  J. Bourhis,et al.  A phase 1 trial of the anti-inhibitory KIR mAb IPH2101 for AML in complete remission. , 2012, Blood.

[6]  J. Doudna,et al.  A Programmable Dual-RNA–Guided DNA Endonuclease in Adaptive Bacterial Immunity , 2012, Science.

[7]  Upendra K. Kar,et al.  Myeloid Suppressor Cell Depletion Augments Antitumor Activity in Lung Cancer , 2012, PloS one.

[8]  H. Kohrt,et al.  Rapid development of exhaustion and down-regulation of eomesodermin limit the antitumor activity of adoptively transferred murine natural killer cells. , 2012, Blood.

[9]  Drew M. Pardoll,et al.  The blockade of immune checkpoints in cancer immunotherapy , 2012, Nature Reviews Cancer.

[10]  Eric Vivier,et al.  Targeting natural killer cells and natural killer T cells in cancer , 2012, Nature Reviews Immunology.

[11]  Vijay S. Pande,et al.  Exploiting a natural conformational switch to engineer an Interleukin-2 superkine , 2012, Nature.

[12]  H. Kleinman,et al.  Multiple uses of basement membrane‐like matrix (BME/Matrigel) in vitro and in vivo with cancer cells , 2011, International journal of cancer.

[13]  P. Bousso,et al.  Intravital imaging reveals distinct dynamics for natural killer and CD8(+) T cells during tumor regression. , 2010, Immunity.

[14]  D. Raulet,et al.  Mature natural killer cells reset their responsiveness when exposed to an altered MHC environment , 2010, The Journal of experimental medicine.

[15]  T. Lakshmikanth,et al.  In vivo tumor cell rejection induced by NK cell inhibitory receptor blockade: Maintained tolerance to normal cells even in the presence of IL‐2 , 2010, European journal of immunology.

[16]  S. Jiang,et al.  Depletion of CD4+CD25+ regulatory T cells enhances natural killer T cell‐mediated anti‐tumour immunity in a murine mammary breast cancer model , 2010, Clinical and experimental immunology.

[17]  M. Caligiuri,et al.  Preclinical characterization of 1-7F9, a novel human anti-KIR receptor therapeutic antibody that augments natural killer-mediated killing of tumor cells. , 2009, Blood.

[18]  M. Manns,et al.  Myeloid derived suppressor cells inhibit natural killer cells in patients with hepatocellular carcinoma via the NKp30 receptor , 2009, Hepatology.

[19]  É. Vivier,et al.  Genetic and antibody-mediated reprogramming of natural killer cell missing-self recognition in vivo , 2009, Proceedings of the National Academy of Sciences.

[20]  C. Roth,et al.  Maturation of mouse NK cells is a 4-stage developmental program. , 2009, Blood.

[21]  É. Vivier,et al.  NK Cell Responsiveness Is Tuned Commensurate with the Number of Inhibitory Receptors for Self-MHC Class I: The Rheostat Model 1 , 2009, The Journal of Immunology.

[22]  Xuetao Cao,et al.  Cancer-Expanded Myeloid-Derived Suppressor Cells Induce Anergy of NK Cells through Membrane-Bound TGF-β11 , 2009, The Journal of Immunology.

[23]  Joseph C. Sun,et al.  Cutting Edge: Viral Infection Breaks NK Cell Tolerance to “Missing Self”1 , 2008, The Journal of Immunology.

[24]  K. Margolin Cytokine therapy in cancer , 2008, Expert opinion on biological therapy.

[25]  D. Raulet,et al.  Regulation of NK cell responsiveness to achieve self‐tolerance and maximal responses to diseased target cells , 2008, Immunological reviews.

[26]  L. Zitvogel,et al.  The role of regulatory T cells in the control of natural killer cells: relevance during tumor progression , 2006, Immunological reviews.

[27]  R. Vance,et al.  Self-tolerance of natural killer cells , 2006, Nature Reviews Immunology.

[28]  Peter Reichelt,et al.  Single step protocol to purify recombinant proteins with low endotoxin contents. , 2006, Protein expression and purification.

[29]  Angel Porgador,et al.  Lethal influenza infection in the absence of the natural killer cell receptor gene Ncr1 , 2006, Nature Immunology.

[30]  L. Lybarger,et al.  Licensing of natural killer cells by host major histocompatibility complex class I molecules , 2005, Nature.

[31]  R. Vance,et al.  A subset of natural killer cells achieves self-tolerance without expressing inhibitory receptors specific for self-MHC molecules. , 2005, Blood.

[32]  A. Chang,et al.  Synergistic effects of IL-12 and IL-18 in skewing tumor-reactive T-cell responses towards a type 1 pattern. , 2005, Cancer research.

[33]  Eric Vivier,et al.  Natural Killer Cell Signaling Pathways , 2004, Science.

[34]  M. Atkins,et al.  Update on the Role of Interleukin 2 and Other Cytokines in the Treatment of Patients with Stage IV Renal Carcinoma , 2004, Clinical Cancer Research.

[35]  J. Blenis,et al.  ERK and p38 MAPK-Activated Protein Kinases: a Family of Protein Kinases with Diverse Biological Functions , 2004, Microbiology and Molecular Biology Reviews.

[36]  H. Kaufman,et al.  Insertion of interleukin-2 (IL-2) and interleukin-12 (IL-12) genes into vaccinia virus results in effective anti-tumor responses without toxicity. , 2002, Vaccine.

[37]  R. Truitt,et al.  Characterization of a Murine NKT Cell Tumor Previously Described as an Acute Myelogenous Leukemia , 2002, Leukemia & lymphoma.

[38]  P. Marrack,et al.  Observation of antigen-dependent CD8+ T-cell/ dendritic cell interactions in vivo. , 2001, Cellular immunology.

[39]  A. Diefenbach,et al.  Rae1 and H60 ligands of the NKG2D receptor stimulate tumour immunity , 2001, Nature.

[40]  P. Grufman,et al.  Innate and adaptive immunity to tumors: IL‐12 is required for optimal responses , 2000, European journal of immunology.

[41]  R. Glas,et al.  Recruitment and Activation of Natural Killer (Nk) Cells in Vivo Determined by the Target Cell Phenotype , 2000, The Journal of experimental medicine.

[42]  S. Akira,et al.  IL-12 up-regulates IL-18 receptor expression on T cells, Th1 cells, and B cells: synergism with IL-18 for IFN-gamma production. , 1998, Journal of immunology.

[43]  H. Okamura,et al.  LPS-Stimulated SJL Macrophages Produce IL-12 and IL-18 That Inhibit IgE Production In Vitro by Induction of IFN-γ Production from CD3intIL-2Rβ+ T Cells , 1998, The Journal of Immunology.

[44]  Jin Hong Liu,et al.  Control of Lytic Function by Mitogen-activated Protein Kinase/Extracellular Regulatory Kinase 2 (ERK2) in a Human Natural Killer Cell Line: Identification of Perforin and Granzyme B Mobilization by Functional ERK2 , 1998, The Journal of experimental medicine.

[45]  P. Lollini,et al.  Interleukin 12 gene therapy of MHC-negative murine melanoma metastases. , 1998, Cancer research.

[46]  G. Trinchieri,et al.  Interleukin-12 and interleukin-18 synergistically induce murine tumor regression which involves inhibition of angiogenesis. , 1998, The Journal of clinical investigation.

[47]  P. A. Peterson,et al.  Major histocompatibility complex (MHC)-encoded HAM2 is necessary for antigenic peptide loading onto class I MHC molecules. , 1992, The Journal of biological chemistry.

[48]  M. Bevan,et al.  Ham-2 corrects the class I antigen-processing defect in RMA-S cells , 1992, Nature.

[49]  R. Jaenisch,et al.  MHC class I deficiency: susceptibility to natural killer (NK) cells and impaired NK activity. , 1991, Science.

[50]  R. Jaenisch,et al.  Rejection of class I MHC-deficient haemopoietic cells by irradiated MHC-matched mice , 1991, Nature.

[51]  H. Ljunggren,et al.  Selective rejection of H–2-deficient lymphoma variants suggests alternative immune defence strategy , 1986, Nature.

[52]  H. Ljunggren,et al.  Host resistance directed selectively against H-2-deficient lymphoma variants. Analysis of the mechanism , 1985, The Journal of experimental medicine.

[53]  F. Garrido,et al.  MHC antigens and tumor escape from immune surveillance. , 2001, Advances in cancer research.